Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 31.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 196,121 shares of the company’s stock after acquiring an additional 47,180 shares during the quarter. Russell Investments Group Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,791,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Signaturefd LLC grew its stake in Teva Pharmaceutical Industries by 85.7% in the 4th quarter. Signaturefd LLC now owns 2,962 shares of the company’s stock valued at $27,000 after acquiring an additional 1,367 shares during the period. MML Investors Services LLC lifted its holdings in Teva Pharmaceutical Industries by 4.8% in the 3rd quarter. MML Investors Services LLC now owns 33,242 shares of the company’s stock valued at $268,000 after purchasing an additional 1,536 shares in the last quarter. X Square Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 0.6% in the 3rd quarter. X Square Capital LLC now owns 254,140 shares of the company’s stock valued at $2,051,000 after purchasing an additional 1,624 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Teva Pharmaceutical Industries by 15.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 12,690 shares of the company’s stock valued at $119,000 after purchasing an additional 1,713 shares in the last quarter. Finally, Yousif Capital Management LLC lifted its holdings in Teva Pharmaceutical Industries by 5.0% in the 1st quarter. Yousif Capital Management LLC now owns 50,681 shares of the company’s stock valued at $476,000 after purchasing an additional 2,425 shares in the last quarter. Institutional investors and hedge funds own 50.39% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.5 %

Shares of TEVA opened at $7.95 on Tuesday. The firm has a market cap of $8.83 billion, a P/E ratio of -5.52, a price-to-earnings-growth ratio of 2.15 and a beta of 1.19. Teva Pharmaceutical Industries Limited has a 12-month low of $6.78 and a 12-month high of $11.44. The company’s 50-day moving average price is $8.67 and its 200 day moving average price is $9.29. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 2.28.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last issued its quarterly earnings data on Wednesday, May 10th. The company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.18). The company had revenue of $3.66 billion during the quarter, compared to analysts’ expectations of $3.60 billion. Teva Pharmaceutical Industries had a negative net margin of 10.73% and a positive return on equity of 27.58%. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 16,491 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $9.93, for a total value of $163,755.63. Following the completion of the transaction, the vice president now directly owns 52,449 shares of the company’s stock, valued at approximately $520,818.57. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 16,491 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $9.93, for a total value of $163,755.63. Following the completion of the transaction, the vice president now directly owns 52,449 shares of the company’s stock, valued at approximately $520,818.57. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Sven Dethlefs sold 19,355 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $9.93, for a total value of $192,195.15. Following the completion of the transaction, the executive vice president now directly owns 223,447 shares of the company’s stock, valued at $2,218,828.71. The disclosure for this sale can be found here. Insiders sold a total of 158,884 shares of company stock valued at $1,572,797 in the last three months. 0.82% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on TEVA. Barclays raised their price objective on Teva Pharmaceutical Industries from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Thursday, February 9th. Evercore ISI upgraded Teva Pharmaceutical Industries from an “in-line” rating to an “outperform” rating in a report on Thursday, May 18th. Finally, StockNews.com began coverage on Teva Pharmaceutical Industries in a report on Thursday, May 18th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.75.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.